{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:59:38Z","timestamp":1790650778173,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["30770782"],"award-info":[{"award-number":["30770782"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["30870898"],"award-info":[{"award-number":["30870898"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["7132063"],"award-info":[{"award-number":["7132063"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NARSAD","award":["20314"],"award-info":[{"award-number":["20314"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.schres.2015.10.038","type":"journal-article","created":{"date-parts":[[2015,11,6]],"date-time":"2015-11-06T01:00:40Z","timestamp":1446771640000},"page":"16-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Increased interleukin-2 serum levels were associated with psychopathological symptoms and cognitive deficits in treatment-resistant schizophrenia"],"prefix":"10.1016","volume":"169","author":[{"given":"Yunlong","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiren","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-De","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovana B.","family":"Zunta-Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jair C.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-7515","authenticated-orcid":false,"given":"Xiang Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.schres.2015.10.038_bb0005","doi-asserted-by":"crossref","first-page":"144","DOI":"10.9758\/cpn.2013.11.3.144","article-title":"Effects of antipsychotics on the inflammatory response system of patients with schizophrenia in peripheral blood mononuclear cell cultures","volume":"11","author":"Al-Amin","year":"2013","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.schres.2015.10.038_bb0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pnpbp.2012.08.015","article-title":"Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology","volume":"42","author":"Altamura","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2015.10.038_bb0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.schres.2014.12.037","article-title":"Altered IL-2, IL-6 and IL-8 serum levels in schizophrenia patients with tardive dyskinesia","volume":"162","author":"An","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.10.038_bb9000","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.physbeh.2014.02.032","article-title":"Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia","volume":"129","author":"Asevedo","year":"2014","journal-title":"Physiol. Behav."},{"issue":"8","key":"10.1016\/j.schres.2015.10.038_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000692","article-title":"Altered T-cell function in schizophrenia: a cellular model to investigate molecular disease mechanisms","volume":"2","author":"Craddock","year":"2007","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.schres.2015.10.038_bb0025","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bbi.2006.02.002","article-title":"Cytokines in schizophrenia and the effects of antipsychotic drugs","volume":"20","author":"Drzyzga","year":"2006","journal-title":"Brain Behav. Immun."},{"issue":"2\u20133","key":"10.1016\/j.schres.2015.10.038_bb0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.psychres.2008.11.007","article-title":"Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR)","volume":"176","author":"Freudenreich","year":"2010","journal-title":"Psychiatry Res."},{"issue":"4","key":"10.1016\/j.schres.2015.10.038_bb0035","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.biopsych.2013.12.002","article-title":"The cytokine model of schizophrenia: emerging therapeutic strategies","volume":"75","author":"Girgis","year":"2014","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2015.10.038_bb0040","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3109\/08039488.2014.986761","article-title":"Role of T helper lymphokines in the immune-inflammatory pathophysiology of schizophrenia: systematic review and meta-analysis","volume":"69","author":"Guo","year":"2015","journal-title":"Nord. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2015.10.038_bb0045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21st century","volume":"29","author":"Howes","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2015.10.038_bb0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1600-065X.2008.00697.x","article-title":"Interleukin-2 in the development and control of inflammatory disease","volume":"226","author":"Hoyer","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.schres.2015.10.038_bb0055","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2015.10.038_bb0060","article-title":"Is there a role for immune-to-brain communication in schizophrenia?","author":"Khandaker","year":"2015","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.schres.2015.10.038_bb0065","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S2215-0366(14)00122-9","article-title":"Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment","volume":"2","author":"Khandaker","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2015.10.038_bb0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0920-9964(99)00171-1","article-title":"Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics","volume":"44","author":"Kim","year":"2000","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.10.038_bb0080","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1176\/appi.ajp.157.5.683","article-title":"Cytokines and the brain: implications for clinical psychiatry","volume":"157","author":"Kronfol","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2015.10.038_bb0085","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1037\/0735-7044.113.5.1030","article-title":"Influence of acute and repeated interleukin-2 administration on spatial learning, locomotor activity, exploratory behaviors, and anxiety","volume":"113","author":"Lacosta","year":"1999","journal-title":"Behav. Neurosci."},{"issue":"2","key":"10.1016\/j.schres.2015.10.038_bb0090","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000026457","article-title":"Central monoamine activity following acute and repeated systemic interleukin-2 administration","volume":"8","author":"Lacosta","year":"2000","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.schres.2015.10.038_bb0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.schres.2015.10.038_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0920-9964(98)00034-6","article-title":"The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6","volume":"32","author":"Lin","year":"1998","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2015.10.038_bb0110","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.conb.2011.10.018","article-title":"Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia?","volume":"22","author":"Lisman","year":"2012","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.schres.2015.10.038_bb0115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.psychres.2012.01.002","article-title":"Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia","volume":"198","author":"Liu","year":"2012","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2015.10.038_bb0120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0924-977X(99)00062-0","article-title":"Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics","volume":"10","author":"Maes","year":"2000","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2015.10.038_bb0125","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2015.10.038_bb0130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000356538","article-title":"Immunology of schizophrenia","volume":"21","author":"M\u00fcller","year":"2014","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.schres.2015.10.038_bb0135","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF03033242","article-title":"Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission","volume":"10","author":"Muller","year":"2006","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.schres.2015.10.038_bb0140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11011-008-9114-5","article-title":"Neuropsychiatric disorders related to interferon and interleukins treatment","volume":"24","author":"Myint","year":"2009","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.schres.2015.10.038_bb0145","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pnpbp.2012.10.022","article-title":"The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia","volume":"48","author":"Na","year":"2014","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2015.10.038_bb0150","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0920-9964(97)00059-5","article-title":"A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?","volume":"26","author":"Naudin","year":"1997","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.10.038_bb0155","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0006-8993(92)91704-I","article-title":"Effect of chronic treatment with recombinant interleukin-2 on the central nervous system of adult and old mice","volume":"591","author":"Nemni","year":"1992","journal-title":"Brain Res."},{"key":"10.1016\/j.schres.2015.10.038_bb0160","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1176\/appi.neuropsych.12020021","article-title":"Association of interleukin 2 (IL-2), interleukin 6 (IL-6), and TNF-alpha (TNF\u03b1) gene polymorphisms with paranoid schizophrenia in a Polish population","volume":"25","author":"Paul-Samojedny","year":"2013","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"key":"10.1016\/j.schres.2015.10.038_bb0165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0167-0115(00)00229-9","article-title":"Cloning the full-length IL-2\/15 receptor-\u03b2 cDNA sequence from mouse brain: evidence of enrichment in hippocampal formation neurons","volume":"98","author":"Petitto","year":"2001","journal-title":"Regul. Pept."},{"key":"10.1016\/j.schres.2015.10.038_bb0170","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/(SICI)1097-4547(19990515)56:4<441::AID-JNR11>3.0.CO;2-G","article-title":"Impaired learning and memory and altered hippocampal neurodevelopment resulting from IL-2 gene deletion","volume":"56","author":"Petitto","year":"1999","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.schres.2015.10.038_bb0175","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/978-1-62703-071-7_15","article-title":"Interleukin-2 and the brain: dissecting central versus peripheral contributions using unique mouse models","volume":"934","author":"Petitto","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.schres.2015.10.038_bb0180","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/978-1-61779-458-2_27","article-title":"Interleukin-2 and the septohippocampal system: intrinsic actions and autoimmune processes relevant to neuropsychiatric disorders","volume":"829","author":"Petitto","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.schres.2015.10.038_bb0185","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2015.10.038_bb0190","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.schres.2012.10.020","article-title":"Cognition and the five-factor model of the Positive and Negative Syndrome Scale in schizophrenia","volume":"143","author":"Rodriguez-Jimenez","year":"2013","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2015.10.038_bb0195","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00406-005-0603-9","article-title":"IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia","volume":"256","author":"Schwarz","year":"2006","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2015.10.038_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cyto.2009.05.005","article-title":"Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients","volume":"47","author":"Singh","year":"2009","journal-title":"Cytokine"},{"issue":"45","key":"10.1016\/j.schres.2015.10.038_bb0205","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0306-9877(95)90062-4","article-title":"The macrophage-T-lymphocyte theory of schizophrenia: additional evidence","volume":"95","author":"Smith","year":"1995","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.schres.2015.10.038_bb0210","article-title":"Neuroimmune biomarkers in schizophrenia","author":"Tomasik","year":"2014","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2015.10.038_bb0215","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.schres.2013.10.011","article-title":"Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis","volume":"151","author":"Tourjman","year":"2013","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2015.10.038_bb0220","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2012.01.031","article-title":"Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia","volume":"137","author":"Wallwork","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.10.038_bb0225","article-title":"Clinical studies of neuroinflammatory mechanisms in schizophrenia","author":"Watkins","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.10.038_bb0230","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.psychres.2010.12.017","article-title":"The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia","volume":"189","author":"Xiong","year":"2011","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2015.10.038_bb0235","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-3956(02)00023-7","article-title":"Decreased production of interleukin-2 (IL-2), IL-2 secreting cells and CD4+ cells in medication-free patients with schizophrenia","volume":"36","author":"Zhang","year":"2002","journal-title":"J. Psychiatr. Res."},{"issue":"2\u20133","key":"10.1016\/j.schres.2015.10.038_bb0240","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0920-9964(01)00296-1","article-title":"Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology","volume":"57","author":"Zhang","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.10.038_bb0245","doi-asserted-by":"crossref","first-page":"940","DOI":"10.4088\/JCP.v65n0710","article-title":"Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia","volume":"65","author":"Zhang","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2015.10.038_bb0250","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00213-008-1295-4","article-title":"Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics","volume":"201","author":"Zhang","year":"2008","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.schres.2015.10.038_bb0255","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00213-012-2643-y","article-title":"Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia","volume":"222","author":"Zhang","year":"2012","journal-title":"Psychopharmacology"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996415300384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996415300384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T23:45:53Z","timestamp":1569109553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996415300384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":50,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0920996415300384"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2015.10.038","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased interleukin-2 serum levels were associated with psychopathological symptoms and cognitive deficits in treatment-resistant schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2015.10.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}